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Abstract
Background: To examine the effect of genetic variation in APOE, IDE and IL1B on the response to induced ketosis
in the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in subjects with mild to moderate
Alzheimer’s disease (AD).
Methods: Genotype effects on ADAS-Cog scores from a randomized, double-blind, placebo-controlled study in
mild to moderate AD were examined by an overall two way analysis of variance. In addition, interactions with the
carriage status of the epsilon 4 allele of the APOE gene (APOE4) were examined.
Results: Significant differences in response to induced ketosis were found among non-carriers of putative gain-of-
function polymorphisms in rs1143627 and rs16944 in the IL1B gene and among variants of the polymorphism
rs2251101 in the IDE gene. Significant differences were found among non-carriers of the APOE4 gene, with notable
improvement among the E3/E3 genotype group.
Conclusions: Variants in APOE, IL1B and IDE may influence the cognitive response to induced ketosis in patients
with mild to moderate AD.
Trial registration: This trial was registered with ClinicalTrials.gov, registry number NCT00142805.
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Background
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease. The major risk factors for the most com-
m o nf o r mo fA D ,k n o w na sl a t eo n s e to rs p o r a d i cA D ,
are age and possession of one or more copies of the
epsilon 4 variant of the apolipoprotein E gene (APOE4).
APOE4 behaves in a dominant dose-dependent manner.
One copy of APOE4 increases the risk of developing AD
by about 3 fold, while two copies increases the risk
approximately 10 fold [1,2].
Alzheimer’s disease is characterized by an early and
progressive decrease in the cerebral metabolic rate of
glucose (CMRglc) [3-5]. The primary regions affected in
AD are the posterior cingulate and the parietal, tem-
poral, and prefrontal cortices. These regions correlate
with the highly metabolically active default network,
suggesting a metabolic link between hypometabolism,
amyloid deposition, and cell atrophy (for review see [6]).
The declines in CMRglc in AD could be attributed to
loss of cells or synaptic fields, however, decreased rates
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energy generating genes [8] have been observed in AD,
suggesting an underlying metabolic defect in these brain
regions [9].
Under normal conditions, the brain is dependent
almost exclusively on glucose and few other substrates
are metabolized [10]. Therefore, declines in glucose uti-
lization can result in severe impairment. Under condi-
tions of low glucose availability, such as during fasting
or low carbohydrate intake, the body will mobilize
ketone bodies, from energy-rich fat stores, which can
provide an alternative substrate for glucose metabolism
in the brain [11]. The endogenously produced com-
pounds b-hydroxybutyrate, acetoacetate and acetone are
normally referred to as ketone bodies. Due to their effi-
cient metabolism and ability to substitute for glucose,
ketone bodies offer a potential therapeutic benefit for
AD [12], as well as other neurological disorders [13].
Previous studies have demonstrated that the induction
of ketosis in mild to moderate AD patients improves
scores in the Alzheimer’s Disease Assessment Scale
-Cognitive subscale (ADAS-Cog) relative to placebo
among non-carriers of the APOE4 allele using both
acute [14] and chronic [15] dosing regimens. Despite
the replication of these findings, it is unclear why E4(-)
subjects would respond to ketosis while E4(+) subjects
would not. Some evidence suggests that E4(+) subjects
may have greater mitochondrial dysfunction relative to
E4(-) subjects (for review see [16]) and therefore may
not metabolize ketone bodies as well. Alternatively, dif-
ferential insulin signaling seen in AD patients based on
E4 carriage status may affect transport and metabolism
of ketone bodies.
To gain further insight into this phenomenon, and to
provide direction for future research, other genetic mar-
kers were tested for their ability to modulate perfor-
mance on the ADAS-Cog test during induced ketosis in
mild to moderate AD patients. Here we report the
effects of polymorphisms in insulin degrading enzyme
(IDE)a n di n t e r l e u k i n1 - b e t a( IL1B)o nA D A S - C o g
scores after 45 and 90 days of a ketogenic therapy fol-
lowed by a two week washout, day 104. A report detail-
ing the present study population, the overall results, and
the APOE4 effects on cognitive outcomes was previously
published [15].
Ketosis was induced by the administration of AC-
1202, a formulation of medium chain triglycerides
(MCTs). MCTs are triglycerides with fatty acid chains of
between 5 and 12 carbons The catabolism of MCTs dif-
fers substantially from the more common long chain tri-
glycerides (LCTs). MCTs are immune to the regulation
of LCT catabolism and are well known for their ability
to induce ketosis after oral administration (for review
see [17]).
Insulin degrading enzyme is a zinc binding metallo-
protease encoded by the IDE gene located on chromo-
some 10. The Ide protein degrades a variety of short
polypeptides including insulin and amyloid beta [18].
Polymorphisms in the region of the IDE g e n eh a v eb e e n
implicated as risk factors in AD (for review see [2]).
Neuroinflammation has also been considered a feature
of AD and may influence risk and rate of progression of
the disease [19]. Interleukin 1beta is a proinflammatory
cytokine encoded by the IL1B gene located on chromo-
some 2. Interleukin levels are normally low in the CNS
but are elevated after acute injury and in chronic neuro-
degenerative diseases such as AD [20]. In addition, for
each marker, the interaction with E4 carriage status was
examined.
Methods
The analysis presented here is an extension of previously
reported results of a study examining the induction of
mild ketosis in patients with mild to moderate AD. As
reported in the earlier study [15], an oral ketogenic
compound, AC-1202, was tested in patients with prob-
able mild to moderate AD to examine if ketosis could
improve cognitive performance. AC-1202 was adminis-
tered daily for 90 days in 152 subjects in a US-based,
randomized, double-blind, placebo-controlled, parallel-
group study. Subjects were not asked to change their
diets and continued taking approved AD medications.
The results of the 90-day study found a significant dif-
ference between AC-1202 and Placebo in mean change
from Baseline in ADAS-Cog score on Day 45. Based on
previous acute dosing study [14], results of cognitive
tests were stratified by APOE4 carriage status. Signifi-
cant differences were reported between AC-1202 and
Placebo in mean change from Baseline in ADAS-Cog
score on both Day 45 and Day 90 among participants
who were non-carriers of the APOE4 allele. Supporting
the improvement relative to placebo by administration
of AC-1202, a significant pharmacologic response was
observed between serum b-hydroxybutyrate levels and
change in ADAS-Cog scores in the non-carriers of
APOE4. Detailed description of this study and its out-
comes has been previously published [15].
Ethics
The trial was carried-out in accordance with the princi-
ples of the Declaration of Helsinki and with institutional
review board approval (Essex Institutional Review Board,
Lebanon, NJ). Subjects and their caregivers provided
written informed consent, which included an optional
written provision for genotyping. For genetic consent,
participants could consent to be tested for APOE geno-
type only, for any additional DNA markers only, for
both, or for neither. Genetic consent was not required
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shared with physicians, site personnel, or study
participants.
Registration
This trial was registered with ClinicalTrials.gov, registry
number NCT00142805, information available at http://
clinicaltrials.gov/ct2/show/NCT00142805.
Study design
This was a randomized, double-blind, placebo-con-
trolled, parallel, multi-center trial sponsored by Accera,
Inc. of Broomfield, CO. It was conducted between Octo-
ber 5, 2004 and June 29, 2006 at 23 treatment centers
located within the United States. The study recruited
outpatients with a diagnosis of probable AD of mild to
moderate severity according to National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) and DSM IV criteria,
with a MMSE score of between 14 and 24 (inclusive) at
Screen. A CT or MRI within 24 months prior to Screen
had to show no signs of tumor, structural abnormality,
or degenerative disease. Subjects were required to have
a Modified Hachinski Ischemia Scale score ≤4. Partici-
pants were randomized to receive either daily doses of
AC-1202 or matching Placebo for 90 days. To acclimate
participants to investigational product, subjects received
a one-half dose daily during the first week of the study.
After this one week titration, participants were
instructed to take a full dose. A full dose of active con-
tained 20 grams of MCTs. The effects of the interven-
tion on cognitive performance were measured at 45 and
90 days post-Baseline and after a two week washout on
Day 104. Primary cognitive outcome was change from
Baseline in ADAS-Cog scores compared to Placebo. Par-
t i c i p a n t si nt h es t u d yw e r ea l l o w e dt or e m a i no nc u r -
rently prescribed AD medications, provided they were
on stable dosing for at least three months prior to
enrollment and did not change dosing during the course
of the study. Most participants (> 75%) were on one or
more currently approved AD medications. Placebo and
AC-1202 groups were well matched for demographic
parameters. For detailed description of study and parti-
cipants see Henderson et. al. [15].
Subject disposition
Two hundred fifty-three subjects were screened at 23
clinical sites located within the United States. One hun-
dred one of these participants did not meet inclusion/
exclusion criteria or refused to participate in the study.
One hundred fifty-two participants were enrolled in the
study. At their discretion, participants could consent to
APOE genotyping only, additional genetic markers only,
or both. One hundred thirty-five of the enrolled subjects
consented to genotyping for the APOE locus. One hun-
dred thirty-one subjects consented to both APOE geno-
typing and additional markers. Of these 131 subjects, 11
lacked a post-Baseline visit and no ADAS-Cog data was
available for analysis (Figure 1).
Study material
AC-1202 (caprylic triglyceride, NeoBee 895, Stepan Che-
mical Company) is a structured medium chain triglycer-
ide (MCT) in which greater than 95% of the fatty acids
are caprylic acid (C8:0). NeoBee 895 is an approved
food additive. Consumption of MCTs may give rise to
gastrointestinal distress such as cramping, nausea and
diarrhea. To improve tolerability, caprylic triglyceride
was formulated as an emulsified spray dried powder
consisting of 33% AC-1202 (NeoBee 895), 64% gum
Acacia (Instagum, CNI) and 2.6% syloid (244FP, Grace
Davison). Placebo was formulated to be isocaloric to the
active formulation and consisted of a mixture of 51%
gum acacia, 37% dextrose, 10% safflower oil and 2%
syloid (prepared by The Chemins Company). Investiga-
tional product was given as a powder packaged in 30
gram sachets containing either active (equivalent to 10
grams of AC-1202) or matching Placebo. A full dose
consisted of two sachets (equivalent to 20 grams of AC-
1202). Product was reconstituted in water or other
liquids.
b-hydroxybutyrate testing
Blood samples were taken for serum BHB levels prior to
dosing and 2 hr post-dosing. Levels of serum b-hydroxy-
butyrate were determined using the Stanbio Laboratory
b-hydroxybutyrate test kit (StanBio Inc). Briefly, in the
presence of NAD, ß-hydroxybutyrate is converted to
acetoacetate and NADH by the enzyme ß-hydroxybuty-
rate dehydrogenase. The NADH produced reacts with
p-iodonitrotetrazolium in the presence of diaphorase to
produce a color that is read at 505 nm to determine the
concentration.
Genotyping
High molecular weight DNA was isolated from whole
blood using standard techniques. Apolipoprotein E
(APOE) epsilon 2, 3 and 4 genotyping was performed
using allele specific extension as previously described
[21]. For single nucleotide polymorphisms, genotyping
was performed by amplification of genomic DNA iso-
lated from whole blood and sequencing samples using
standard procedures. Primer pair sequences used for
amplification and sequencing were: IDE rs2251101
CAGCACTTTAGGAGGCCAAG/CTGCCCTTACAGG-
GATGAAA; IL1B rs1143627 and rs16944 CACAAA-
GAGGCAGAGAGACAGA/GTCTTGCAGGGTTGTG
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not be determined and no genotype was assigned.
Cognitive Testing
Subjects were administered the ADAS-Cog test at Base-
line and Days 45, 90 and 104. The ADAS-Cog is one of
the most widely used scales for anti-dementia drugs in
the United States. The ADAS-Cog subscale consists of
11 tasks measuring cognitive abilities in memory, lan-
guage, orientation, and praxis, with a total score ranging
from 0 (no impairment) to 70 (severe impairment). The
higher the ADAS-Cog score, the more impaired the sub-
j e c t .T h e r e f o r e ,l o w e r i n go ft h eA D A S - C o gs c o r ei sa
measure of cognitive improvement.
Statistical Methods
Analysis was done comparing change from Baseline in
ADAS-Cog scores using reported scores between Active
and Placebo treated groups on Days 45, 90 and 104.
Only actual scores for each time point were used in this
analysis. No data was imputed. An overall two way ana-
lysis of variance was used to evaluate cognitive scores by
genotype and treatment interactions at Days 45, 90 and
104.
Results and Discussion
Single Nucleotide Polymorphisms (SNPs) effects on ADAS-
Cog
Single nucleotide polymorphisms (SNPs) rs1143627 and
rs16944 in the promoter region of IL1B and rs2251101
in the 3’ untranslated region of IDE were analyzed for
their effects on ADAS-Cog scores after administration
of AC-1202 or Placebo. The genotypic frequencies of
the SNPs in the study population are listed in Table 1.
Cognitive outcomes associated with common APOE
genotypes were also examined. Mean change from Base-
line in ADAS-Cog scores are shown in Table 2.
For SNP rs2251101 near the IDE gene, heterozygous
C/T subjects administered AC-1202 demonstrated sig-
nificant improvement relative to Placebo at Days 45
(Δ3.96; CI 1.27- 6.66; p = 0.004) and Day 90 (Δ5.71; CI
1.88-9.54; p = 0.004). When participants were categor-
ized as either IDE rs2251101 C/C(-) or IDE rs2251101
C/C(+) based on their carriage status of the C/C geno-
type, significant improvement was found in IDE
rs2251101 C/C(-) subjects administered AC-1202 rela-
tive to Placebo at Days 45 (Δ2.85; CI 1.10-4.61; p =
0.002) and Day 90 (Δ3.21;CI 0.766-5.652; p = 0.011)
(Table 2).
Figure 1 Subject Disposition.
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region of IL1B gene, identical significant effects were
seen for rs1143627 T/T and rs16944 C/C carriers. Both
genotypes demonstrated significant improvement among
those administered AC-1202 relative to Placebo at Days
45 (Δ2.79; CI 0.26-5.33; p = 0.031) and Day 90 (Δ3.70;
CI 0.09-7.30; p = 0.044). Note, rs1143627 T and rs16944
C were in complete linkage disequilibrium in the sample
population.
No significant genotype interactions for any SNPs
were found between AC-1202 and Placebo at Day 104
(Table 2).
APOE genotype effects on ADAS-Cog
Among APOE genotypes, homozygous carriers of the
epsilon 3 allele administered AC-1202 demonstrated sig-
nificant improvement relative to Placebo at Days 45
(Δ5.31; CI 2.15- 8.48; p = 0.0012) and Day 90 (Δ3.98; CI
0.41-7.55; p = 0.030). Carriers of the E4 allele did not
demonstrate significant effects on ADAS-Cog scores.
Subjects who carried a single E4 allele, for example E4/
E3 genotype did not differ significantly from Placebo at
either Day 45 or Day 90 (See Table 2). Consistent with
earlier results, when participants were categorized as
either E4(+) or E4(-) based on their carriage status of
the epsilon 4 allele, significant improvement were found
in E4(-) subjects administered AC-1202 relative to Pla-
cebo at Days 45 (Δ5.35; CI 2.37-8.321; p = 0.0006) and
Day 90 (Δ3.9; CI 0.45-7.35; p = 0.027). Due to the small
number of E4/E4 carriers, it was not possible to exam-
ine dosage effects of E4 on ADAS-Cog scores.
Note, the dataset used in the present study included
only ADAS-Cog scores from a subset of participants
who signed genetic consent for additional markers and
hence the means and p-values differ slightly from the
population who consented to APOE testing as previously
reported [15]. However, the overall findings of signifi-
cance did not change.
Interactions with APOE4
Previous studies have demonstrated a pharmacogenetic
response in cognitive performance by induction of keto-
sis based on APOE4 carriage status. In the present
study, each of the SNPs were examined for an interac-
tion between the SNP genotype and E4 carriage status,
as defined as either E4(-) or E4(+).
Evidence of possible interactions with APOE4 were
defined as genetic combinations that produced enhanced
cognitive improvement at Day 45, Day 90 and Day 104
when compared to the cognitive results for E4(-) sub-
jects alone. As described above, among E4(-) subjects
administered AC-1202, change from Baseline scores on
ADAS-Cog improved an average of -2.16 points on Day
45, -2.27 points on Day 90, and -0.87 points on Day 104.
Specific genotype combinations of IDE and E4(-) as
well as IL1B and E4(-) produced additive improvements
in cognitive performance. Among E4(-) subjects admi-
nistered AC-1202 who were also heterozygous C/T for
the IDE rs2251101SNP, scores on ADAS-Cog improved
from Baseline an average of -4.5 points on Day 45, -7.73
points on Day 90, and -4.5 points on Day 104, all of
which were significantly different from Placebo means
(p < 0.05) (Figure 2A, Table 3). Among E4(-) subjects
administered AC-1202 who were also homozygous for
T/T for the IL1B rs1143627 SNP (all of these subjects
were also homozygous for the C/C allele of rs16944),
scores on ADAS-Cog improved from Baseline an aver-
age of -3.6 points on Day 45, -5.7 points on Day 90 and
-3.3 points on Day 104, all of which were significantly
different from Placebo means (p < 0.05) (Figure 2B,
Table 3). No significant differences between Active and
Placebo were found among E4(+) subjects and any gen-
otypes of IDE or IL1B (Table 4).
Changes in serum b-hydroxybutyrate levels
To examine if differences in cognitive performance were
due to differences in circulating ketone body levels,
serum b-hydroxybutyrate (BHB) levels were compared
between potential responder genotypes. Serum BHB
levels among subjects receiving AC-1202 were compared
between genotypes at Baseline, Day 45 and Day 90. At
Baseline 1/2 dose (10 grams of AC-1202) was adminis-
tered and on Days 45 and 90 full dose (20 grams of AC-
1202). Significant differences were found at the Baseline
visit between E4 carriers and non-carriers (p-value 0.03).
However, this finding did not reproduce at later time
points. Among E4(-) and IDE and IL1B genotypes admi-
nistered AC-1202, there were no significant differences
between BHB levels at any study visit (Table 5).
Table 1 Distribution of genotypes
gene SNP AC-1202 Placebo
Allele Count Frequency Count Frequency
IL1B rs1143627 C 6 0.098 9 0.173
Het 27 0.443 17 0.327
T 28 0.459 26 0.500
Total 61 1 52 1
IL1B rs16944 C 28 0.459 26 0.500
Het 27 0.443 17 0.327
T 6 0.098 9 0.173
Total 61 1 52 1
IDE rs2251101 C 9 0.138 7 0.127
Het 21 0.323 25 0.454
T 35 0.538 23 0.418
Total 65 1 55 1
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Day 45 Change from Baseline
Gene SNP/Allele Genotype AC1202 n Placebo n p-value* Difference (CI)
APOE APOE 3/2 -1.222 3 5.167 2 0.182 6.389(-3.050, 15.828)
APOE APOE 3/3 -2.317 20 2.999 23 0.001 5.315(2.154, 8.476)
APOE APOE 4/2 2.778 3 . 0 na na
APOE APOE 4/3 1.107 28 2.175 19 0.492 1.068(-2.005, 4.142)
APOE APOE 4/4 -1.667 3 -1.167 10 0.884 0.500(-6.306, 7.306)
IDE rs2251101 C 2.375 8 -0.905 7 0.138 3.280(-1.076, 7.635)
IDE rs2251101 Het -1.647 17 2.317 23 0.004 3.964(1.273, 6.656)
IDE rs2251101 T -0.711 30 1.290 23 0.092 2.001(-0.331, 4.333)
IDE c/c IDE c/c (-) IDE - -1.050 47 1.804 46 0.002 2.853(1.100, 4.606)
IDE c/c IDE c/c (+) IDE + 2.375 8 -0.905 7 0.140 3.280(-1.094, 7.654)
IL1B rs1143627 C 1.000 5 2.481 9 0.545 1.481(-3.365, 6.328)
IL1B rs1143627 Het -1.097 24 -0.020 17 0.439 1.078(-1.677, 3.832)
IL1B rs1143627 T -0.768 23 2.026 24 0.031 2.795(0.259, 5.330)
IL1B rs16944 C -0.768 23 2.026 24 0.031 2.795(0.259, 5.330)
IL1B rs16944 Het -1.097 24 -0.020 17 0.439 1.078(-1.677, 3.832)
IL1B rs16944 T 1.000 5 2.481 9 0.545 1.481(-3.365, 6.328)
Day 90 Change from Baseline
APOE APOE 3/2 3.667 1 6.333 1 0.737 2.667(-13.098, 18.431)
APOE APOE 3/3 -2.579 19 1.398 20 0.029 3.977(0.406, 7.548)
APOE APOE 4/2 -3.667 2 . 0 na na
APOE APOE 4/3 1.302 21 0.471 17 0.651 0.831(-2.806, 4.468,)
APOE APOE 4/4 1.667 2 0.867 10 0.854 0.800(-7.835, 9.435)
IDE rs2251101 C 3.905 7 -1.857 7 0.047 5.762(0.074, 11.450)
IDE rs2251101 Het -2.769 13 2.944 19 0.004 5.713(1.883, 9.543)
IDE rs2251101 T -0.931 24 0.446 21 0.392 1.377(-1.803, 4.556)
IDE c/c IDE c/c (-) IDE - -1.577 37 1.633 40 0.011 3.209(0.766, 5.652)
IDE c/c IDE c/c (+) IDE + 3.905 7 -1.857 7 0.049 5.762(0.038, 11.486)
IL1B rs1143627 C -1.083 4 1.815 9 0.396 2.898(-3.859, 9.656)
IL1B rs1143627 Het -0.193 19 -0.044 15 0.940 0.149(-3.735, 4.033)
IL1B rs1143627 T -1.947 19 1.748 20 0.044 3.696(0.093, 7.298)
IL1B rs16944 C -1.947 19 1.748 20 0.044 3.696(0.093, 7.298)
IL1B rs16944 Het -0.193 19 -0.044 15 0.940 0.149(-3.735, 4.033)
IL1B rs16944 T -1.083 4 1.815 9 0.396 2.898(-3.859, 9.656)
Day 104 Change from Baseline
APOE APOE 3/2 -1.333 3 2.333 2 0.474 3.667(-6.443, 13.776)
APOE APOE 3/3 -0.812 23 1.384 21 0.196 2.196(-1.147, 5.538)
APOE APOE 4/2 0.889 3 . 0 na na
APOE APOE 4/3 0.821 26 -0.722 18 0.370 1.543(-1.853, 4.938)
APOE APOE 4/4 -1.083 4 0.933 10 0.543 2.017(-4.535, 8.568)
IDE rs2251101 C 3.762 7 0.952 7 0.331 2.810(-2.895, 8.514)
IDE rs2251101 Het -2.169 18 0.317 20 0.158 2.485(-0.982, 5.953)
IDE rs2251101 T -0.029 33 0.867 22 0.547 0.896(-2.042, 3.834)
IDE c/c IDE c/c (-) IDE - -0.784 51 0.605 42 0.217 1.389(-0.828, 3.606)
IDE c/c IDE c/c (+) IDE + 3.762 7 0.952 7 0.330 2.810(-2.878, 8.497)
IL1B rs1143627 C 0.778 6 0.407 9 0.898 0.370(-5.373, 6.114)
IL1B rs1143627 Het -0.376 24 0.524 14 0.627 0.900(-2.765, 4.565)
IL1B rs1143627 T -0.720 25 0.380 23 0.490 1.100(-2.049, 4.248)
IL1B rs16944 C -0.720 25 0.380 23 0.490 1.100(-2.049, 4.248)
IL1B rs16944 Het -0.376 24 0.524 14 0.627 0.900(-2.765, 4.565)
IL1B rs16944 T 0.778 6 0.407 9 0.898 0.370(-5.373, 6.114)
*p-value < 0.05 bold, < 0.01 bold and underlined. na = not available
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Page 6 of 13Figure 2 Change from Baseline in ADAS-Cog scores among responder genotypes over time. Red markers represent mean change from
Baseline among subjects administered AC-1202. Blue markers represent mean change from Baseline among subjects administered Placebo. Error
bars represent standard error of the mean. A Solid lines and solid markers represent subjects who are APOE4(-). Dotted lines and solid markers
represent mean scores of subjects who are heterozygous for the IDE SNP rs2251101. Dashed lines and open markers represent mean scores of
subjects who were E4(-) and heterozygous for the IDE SNP rs2251101. B Solid lines and solid markers represent subjects who are APOE4(-).
Dotted lines and solid markers represent mean scores of subjects who are homozygous for the IL1B SNP rs1143627 T allele. Dashed lines and
open markers represent mean scores of subjects who were E4(-) and homozygous for the IL1B SNP rs1143627 T allele. Asterisks represent
significant difference between AC-1202 and Placebo means (p-value < 0.05).
Henderson and Poirier BMC Medical Genetics 2011, 12:137
http://www.biomedcentral.com/1471-2350/12/137
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ketogenic compounds MCTs improved cognitive perfor-
mance in mild to moderate AD patients relative to Pla-
cebo. Yet, the improvement was largely restricted to
non-carriers of the AD risk factor APOE4 [14,15]. In the
present study, additional genetic markers were examined
for their ability to influence cognitive performance at
specific time points during a 90 day dosing of MCTs. In
general, the low number of subjects in the study did not
allow for definitive analysis, and the results should be
considered exploratory.
Ketone bodies are produced mainly by the liver from
fatty acids (FA) during periods of low carbohydrate
availability. Ketogenesis and the utilization of ketone
bodies is regulated at several key steps that, under nor-
mal feeding conditions, prevent substantial amounts of
ketone bodies from being produced. Ketogenesis
requires abundant circulating free fatty acid (FFA) levels
for oxidation in the liver. Thus, conditions, such as high
carbohydrate diet and elevated insulin signaling prevent
ketone body production.
Ketone bodies have several properties that make them
attractive for treating neurodegenerative disorders. Dur-
ing starvation conditions ketone bodies can substitute
for the majority of the brain’s energy requirements [11].
Studies with infused ketone bodies have demonstrated
Table 3 Change in ADAS-Cog scores among APOE4(-) participants
Day 45 Change from Baseline
gene SNP Allele AC1202 n Placebo n p-value* Difference(CI)
IDE IDE- IDE c/c (-) -2.772 19 2.071 23 0.000 4.843(2.568, 7.118)
IDE IDE+ IDE c/c (+) 0.667 4 -0.667 1 0.745 1.333(-6.870, 9.536)
IDE rs2251101 C 0.667 4 -0.667 1 0.744 1.333(-6.867, 9.534)
IDE rs2251101 Het -4.500 6 1.775 12 0.001 6.275(2.608, 9.942)
IDE rs2251101 T -1.974 13 2.394 11 0.005 4.368(1.364, 7.373)
IL1B rs1143627 C 0.333 3 4.333 3 0.192 4.000(-2.103, 10.103)
IL1B rs1143627 Het -2.083 8 0.524 7 0.180 2.607(-1.261, 6.476)
IL1B rs1143627 T -3.633 10 1.997 13 0.001 5.631(2.487, 8.775)
IL1B rs16944 C -3.633 10 1.997 13 0.001 5.631(2.487, 8.775)
IL1B rs16944 Het -2.083 8 0.524 7 0.180 2.607(-1.261, 6.476)
IL1B rs16944 T 0.333 3 4.333 3 0.192 4.000(-2.103, 10.103)
Day 90 Change from Baseline
IDE IDE- IDE c/c (-) -3.729 16 2.156 19 0.003 5.885(2.192, 9.578)
IDE IDE+ IDE c/c (+) 3.583 4 -5.333 1 0.146 8.917(-3.252, 21.086)
IDE rs2251101 C 3.583 4 -5.333 1 0.132 8.917(-2.834, 20.667)
IDE rs2251101 Het -7.733 5 2.956 9 0.001 10.689(4.827, 16.551)
IDE rs2251101 T -1.909 11 1.437 10 0.148 3.346(-1.246, 7.938)
IL1B rs1143627 C -1.000 3 3.222 3 0.370 4.222(-5.241, 13.685)
IL1B rs1143627 Het -0.250 8 -0.389 6 0.964 0.139(-6.120, 6.398)
IL1B rs1143627 T -5.667 8 2.463 10 0.005 8.130(2.633, 13.627)
IL1B rs16944 C -5.667 8 2.463 10 0.005 8.130(2.633, 13.627)
IL1B rs16944 Het -0.250 8 -0.389 6 0.964 0.139(-6.120, 6.398)
IL1B rs16944 T -1.000 3 3.222 3 0.370 4.222(-5.241, 13.685)
Day 104 Change from Baseline
IDE IDE- IDE c/c (-) -1.909 22 1.686 21 0.026 3.595(0.451, 6.739)
IDE IDE+ IDE c/c (+) 4.833 4 -3.333 1 0.160 8.167(-3.356, 19.690)
IDE rs2251101 C 4.833 4 -3.333 1 0.152 8.167(-3.117, 19.451)
IDE rs2251101 Het -4.546 8 0.867 10 0.028 5.413(0.625, 10.200)
IDE rs2251101 T -0.402 14 2.430 11 0.167 2.833(-1.234, 6.899)
IL1B rs1143627 C 1.444 3 -0.333 3 0.670 1.778(-6.598, 10.153)
IL1B rs1143627 Het 0.478 9 1.611 6 0.674 1.133(-4.273, 6.540)
IL1B rs1143627 T -3.333 12 0.894 12 0.048 4.228(0.040, 8.415)
IL1B rs16944 C -3.333 12 0.894 12 0.048 4.228(0.040, 8.415)
IL1B rs16944 Het 0.478 9 1.611 6 0.674 1.133(-4.273, 6.540)
IL1B rs16944 T 1.444 3 -0.333 3 0.670 1.778(-6.598, 10.153)
*p-value < 0.05 bold, < 0.01 bold and underlined.
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Page 8 of 13that even in the presence of normal glucose, the brain
will metabolize ketone bodies [22]. Therefore, in condi-
tions where glucose use is impaired, ketone bodies may
offer a substitute fuel. This is the rationale for the suc-
cessful use of ketogenic diets in GLUT1 deficiency syn-
drome, where the brain cannot transport sufficient
glucose for normal function and ketones can substitute
for the lack of glucose [23]. Similarly, the regional
decreases in CMR(glc) seen in AD may benefit from the
exogenous supplementation with ketone bodies (for
review see [12]).
The SNP rs2251101 is located in the 3’ un-translated
region of the IDE gene. The C allele has been associated
with a putative reduction of function haplotype of IDE.
Homozygous carriers of the C allele were found to pre-
sent high fasting and post-prandial insulin levels, as well
as greater body mass index, suggestive of low Ide activ-
ity [24]. In the present study, heterozygous C/T carriers
as well as grouped non-C/C carriers administered AC-
1202 had significantly improved ADAS-Cog scores at
Days 45 and 90 relative to Placebo subjects of the same
genotype. Homozygous C/C carriers may have reduced
Ide activity and hence higher insulin levels. High insulin
levels may reduce levels of monocarboxylate transpor-
ters and inhibit the ability to respond to induced ketosis.
It is well recognized that insulin signaling promotes fatty
Table 4 Change in ADAS-Cog scores among APOE4(+) participants
Day 45 Change from Baseline
gene SNP Allele AC1202 n Placebo n p-value Difference(CI)
IDE IDE- IDE c/c (-) 0.119 28 1.536 23 0.276 1.417(-1.163, 3.998)
IDE IDE+ IDE c/c (+) 4.083 4 -0.944 6 0.094 5.028(-0.892, 10.947)
IDE rs2251101 C 4.083 4 -0.944 6 0.091 5.028(-0.827, 10.883)
IDE rs2251101 Het -0.091 11 2.909 11 0.126 3.000(-0.868, 6.868)
IDE rs2251101 T 0.255 17 0.278 12 0.989 0.023(-3.397, 3.443)
IL1B rs1143627 C 2.000 2 1.556 6 0.908 0.444(-7.234, 8.123)
IL1B rs1143627 Het -0.604 16 -0.400 10 0.914 0.204(-3.587, 3.995)
IL1B rs1143627 T 1.436 13 2.061 11 0.746 0.625(-3.228, 4.477)
IL1B rs16944 C 1.436 13 2.061 11 0.746 0.625(-3.228, 4.477)
IL1B rs16944 Het -0.604 16 -0.400 10 0.914 0.204(-3.587, 3.995)
IL1B rs16944 T 2.000 2 1.556 6 0.908 0.444(-7.234, 8.123)
Day 90 Change from Baseline
IDE IDE- IDE c/c (-) 0.063 21 1.159 21 0.508 1.095(-2.211, 4.402)
IDE IDE+ IDE c/c (+) 4.333 3 -1.278 6 0.143 5.611(-1.965, 13.187)
IDE rs2251101 C 4.333 3 -1.278 6 0.143 5.611(-1.961, 13.183)
IDE rs2251101 Het 0.333 8 2.933 10 0.308 2.600(-2.479, 7.679)
IDE rs2251101 T -0.103 13 -0.455 11 0.872 0.352(-4.035, 4.739)
IL1B rs1143627 C -1.333 1 1.111 6 0.687 2.444(-9.715, 14.603)
IL1B rs1143627 Het -0.152 11 0.185 9 0.894 0.337(-4.723, 5.396)
IL1B rs1143627 T 0.758 11 1.033 10 0.910 0.276(-4.643, 5.194)
IL1B rs16944 C 0.758 11 1.033 10 0.910 0.276(-4.643, 5.194)
IL1B rs16944 Het -0.152 11 0.185 9 0.894 0.337(-4.723, 5.396)
IL1B rs16944 T -1.333 1 1.111 6 0.687 2.444(-9.715, 14.603)
Day 104 Change from Baseline
IDE IDE- IDE c/c (-) 0.069 29 -0.476 21 0.733 0.545(-2.646, 3.737)
IDE IDE+ IDE c/c (+) 2.333 3 1.667 6 0.866 0.667(-7.210, 8.543)
IDE rs2251101 C 2.333 3 1.667 6 0.868 0.667(-7.357, 8.690)
IDE rs2251101 Het -0.267 10 -0.233 10 0.990 0.033(-5.041, 5.108)
IDE rs2251101 T 0.246 19 -0.697 11 0.662 0.943(-3.356, 5.242)
IL1B rs1143627 C 0.111 3 0.778 6 0.871 0.667(-7.534, 8.868)
IL1B rs1143627 Het -0.889 15 -0.292 8 0.814 0.597(-4.480, 5.675)
IL1B rs1143627 T 1.692 13 -0.182 11 0.432 1.874(-2.877, 6.625)
IL1B rs16944 C 1.692 13 -0.182 11 0.432 1.874(-2.877, 6.625)
IL1B rs16944 Het -0.889 15 -0.292 8 0.814 0.597(-4.480, 5.675)
IL1B rs16944 T 0.111 3 0.778 6 0.871 0.667(-7.534, 8.868)
Henderson and Poirier BMC Medical Genetics 2011, 12:137
http://www.biomedcentral.com/1471-2350/12/137
Page 9 of 13acid storage and reduces fatty acid oxidation, while con-
ditions of low insulin signaling, such as fasting, promote
ketogenesis and ketolysis. This mechanism is likely to
operate in the brain [25].
Two SNPs (rs1143627 and rs16944) found in the pro-
moter region of the IL1B gene have been associated
with clinically observed differences in the levels of Il1b
protein in vivo. The SNP rs1143627 C/T is located at
position -31 in the putative TATA box of the IL1B
gene. The SNP rs16944 C/T is located at position -511.
A haplotype, composed of the T allele at -511 and the C
allele at -31, is significantly associated with a two to
threefold increase in lipopolysaccharide (LPS) -induced
Il1b protein secretion [26]. Thus, carriers of this haplo-
type may produce an enhanced inflammatory response
and inhibit their ability to respond to ketosis, while
non-carriers of this haplotype, (subjects who were
homozygous for rs1143627 T and rs16944 C) showed
significant response at Days 45 and 90.
Similar to polymorphisms in IDE, enhanced inflamma-
tory response may inhibit the ability of the cells to uti-
lize ketone bodies by influencing insulin signaling.
Inflammation is well recognized to diminish the rate of
h e p a t i ck e t o g e n e s i s ,p o s s i b l yb yi n c r e a s i n gc i r c u l a t i n g
insulin levels [27]. Notably, due to their unique metabo-
lism, medium chain fatty acids, such as caprylic acid
generated by AC-1202, are immune to the inflammatory
inhibition of ketogenesis [28]. Of note, no significant
differences in serum BHB levels were noted between
IL1B rs1143627 and rs16944 genotypes. One mechanism
by which elevated circulating insulin levels may inhibit
the uptake of ketone bodies is by reduction of monocar-
boxylate transporter proteins, such as monocarboxyate
transporter 1 (MCT1). Consistent with this view, inflam-
mation of the intestine has been associated with
decreased levels of MCT1 [29] and increased reliance
on glucose [30], suggesting that inflammation could
induce a shift away from ketone body metabolism
towards glucose. In addition, inflammation may directly
inhibit cells’ ability to metabolize ketone bodies. For
example, treating rats with LPS was found to cause
nitration and reduced activity of the protein succinyl-
CoA:3-oxoacid CoA transferase (SCOT; EC 2.8.3.5) [31].
SCOT catalyzes the formation of acetyl-CoA from
Table 5 b-hydroxybutyrate levels among responder genotypes
APOE4 status SNP Genotype N Mean BHB mM Std Error Lower 95% Upper 95% p-value*
Baseline Post-dose (1/2 dose)
E4- 29 0.121 0.014 0.093 0.148
E4+ 38 0.161 0.012 0.137 0.185 0.030
E4- IL1B rs1143627 C/C 3 0.103 0.032 0.037 0.170
E4- IL1B rs1143627 C/T 9 0.126 0.019 0.087 0.164
E4- IL1B rs1143627 T/T 14 0.120 0.015 0.089 0.151 0.838
E4- IDE rs2251101 C/C 5 0.096 0.025 0.045 0.147
E4- IDE rs2251101 C/T 9 0.134 0.018 0.097 0.172
E4- IDE rs2251101 T/T 15 0.121 0.014 0.091 0.150 0.471
Day 45 Post-dose (full dose)
E4- 23 0.334 0.047 0.240 0.428
E4+ 33 0.355 0.039 0.276 0.434 0.730
E4- IL1B rs1143627 C/C 3 0.227 0.102 0.013 0.441
E4- IL1B rs1143627 C/T 8 0.431 0.062 0.300 0.562
E4- IL1B rs1143627 T/T 10 0.278 0.056 0.161 0.395 0.132
E4- IDE rs2251101 C/C 4 0.470 0.099 0.263 0.677
E4- IDE rs2251101 C/T 6 0.315 0.081 0.146 0.484
E4- IDE rs2251101 T/T 13 0.301 0.055 0.186 0.416 0.338
Day 90 Post-dose(full dose)
E4- 20 0.301 0.076 0.147 0.454
E4+ 22 0.471 0.072 0.325 0.617 0.111
E4- IL1B rs1143627 C/C 3 0.193 0.144 -0.111 0.498
E4- IL1B rs1143627 C/T 8 0.378 0.088 0.191 0.564
E4- IL1B rs1143627 T/T 8 0.296 0.088 0.110 0.483 0.544
E4- IDE rs2251101 C/C 4 0.123 0.113 -0.116 0.361
E4- IDE rs2251101 C/T 5 0.470 0.101 0.257 0.683
E4- IDE rs2251101 T/T 11 0.288 0.068 0.144 0.432 0.099
*ANOVA of means
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Page 10 of 13acetoacetate and is the rate limiting step in the metabo-
lism of ketone bodies. Therefore, inhibition of uptake or
metabolism of ketone bodies by an enhanced inflamma-
tory response due to polymorphisms in IL1B may
reduce the ability of an AD patient to respond to
induced ketosis (Figure 3).
S u c ham o d e lm a ye x p l a i nt h ea d d i t i v ee f f e c t ss e e n
among E4(-) subjects without the reduction of function
IDE genotype rs2251101 C/C and without the proinflam-
matory genotype of IL1B rs1143627 C/C. Absence of
these genotypes is predicted to lead to decreased insulin
levels. The lower levels of insulin in an E4(-) background
may be insufficient to overcome the mild insulin resis-
tance and hence these subjects can respond to induced
ketosis (Figure 3). In contrast, the relative insulin sensi-
tivity of E4(+) subjects may prevent them from respond-
ing to ketosis in any genetic background [32,33].
When IDE and IL1B responder genotypes were exam-
ined in E4(+) carriers, no significant effects were
observed, yet an additive or synergistic effect appears to
be present in E4(-) subjects, suggesting that the effects
seen in the overall genotyped population may have been
driven by the strong response among E4(-) subjects who
also carried the IDE or IL1B responder genotypes. This
is notable by improvement in performance relative to
the Placebo after the two week washout, which suggests
that ketone bodies may confer a durable effect on cogni-
tion, possibly by improving mitochondrial efficiency and
reducing oxidative damage [34] or through improvement
in cerebral lipid environment [35].
Conclusions
In conclusion, despite the relatively small size of this
study, genetic influences on cognitive scores in response
to induced ketosis were noted. The main modulator of
induced ketosis appears to be the carriage status of
APOE4. It may not be a coincidence that APOE4 is also
the major genetic risk factor for late onset AD. The fail-
ure of APOE4 carriers to respond to ketosis may indi-
cate a more insidious metabolic problem. APOE4
carriers may be overly reliant on glucose and hence,
over a lifetime, cerebral neurons are deprived of the
metabolic advantages conferred by ketone body metabo-
lism and this may be crucial to etiology of AD [36].
Importantly, this type of pharmacogenomic profiling not
only offers insights into the disease process, it also
allows targeting of patients who are most likely to
respond to therapy. In this way, better and more effec-
tive therapeutics can be developed.
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